简介: 【摘 要】 目的: 分析研究托伐普坦治疗肝硬化失代偿期难治性腹水患者的临床疗效及安全性。 方法: 选取本院 58例肝硬化失代偿期难治性腹水患者开展本次研究,标本纳入时间范围为 2018年 02月 -2019年 01月,所有患者在常规治疗基础上予以托伐普坦治疗。观察治疗效果及不良反应情况。 结果: 经治疗,显效改善人数为 40人,占比 68.97%,有效改善人数为 16人,占比 27.59%,无效人数为 2人,占比 3.45%,总治疗有效率为 96.55%;58例患者出现口渴、口干等轻微药物不良反应人数为 2人,不良反应发生率为 3.45%。 结论: 在治疗肝硬化失代偿期难治性腹水的过程中应用托伐普坦,达到了预期的治疗目标,同时不会产生较为严重的不良反应,有助于患者生活质量的进一步提升,具有推广价值。 【关键词】 托伐普坦 ;肝硬化 ;失代偿期 ;腹水 [Abstract] Objective: to analyze the clinical efficacy and safety of tovaptan in the treatment of refractory ascites in decompensated cirrhosis. Methods: 58 patients with refractory ascites in decompensated stage of cirrhosis were selected to carry out this study. The sample was included from February 2018 to January 2019. All patients were treated with tovaptan on the basis of routine treatment. The therapeutic effect and adverse reactions were observed. Results: after treatment, the number of significant improvement was 40, accounting for 68.97%, the number of effective improvement was 16, accounting for 27.59%, the number of ineffective was 2, accounting for 3.45%, and the total effective rate was 96.55%; the number of 58 patients with minor adverse reactions such as thirst and dry mouth was 2, and the incidence of adverse reactions was 3.45%. Conclusion: in the treatment of refractory ascites in decompensated cirrhosis, the application of tovaptan has achieved the expected treatment goal, and will not produce more serious adverse reactions, which is helpful to further improve the quality of life of patients, and has the value of promotion.